Novartis AG (NVS) has disclosed a new risk, in the Supply Chain category.
Novartis AG faces a substantial business risk in its supply chain management due to the complexity of its manufacturing processes and reliance on specialized raw materials, some of which come from single sources. The company’s production of sterile, biologic, and advanced therapy products like gene and cell therapies demands precise planning and is vulnerable to disruptions from raw material shortages or geopolitical events. Such disturbances could lead to production halts, supply shortages, and potentially severe implications for both patient health and Novartis AG’s financial stability and reputation.
Overall, Wall Street has a Moderate Buy consensus rating on NVS stock based on 1 Buy and 1 Hold.
To learn more about Novartis AG’s risk factors, click here.
